Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

MedStar Georgetown University Hospital, Washington D.C.

Duke Cancer Center Cary, Cary

Duke University Medical Center, Durham

Emory University Hospital Midtown, Atlanta

Emory University Hospital/Winship Cancer Institute, Atlanta

Emory Saint Joseph's Hospital, Atlanta

UCHealth University of Colorado Hospital, Aurora

City of Hope Comprehensive Cancer Center, Duarte

Stanford Cancer Institute Palo Alto, Palo Alto

University of California Davis Comprehensive Cancer Center, Sacramento

Massachusetts General Hospital Cancer Center, Boston

Brigham and Women's Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston